The abstract is read at the publisher; the summary is JClub's.
LDCT lung cancer screening in Medicare beneficiaries aged 65–78 is linked to less distant-stage SCLC at diagnosis (44.2% vs 70.4%) and better 3-year survival (28.0% vs 10.8%).
- Why it matters: LDCT screening benefits for small cell lung cancer are unclear, despite evidence for earlier detection and mortality reduction in other lung cancer types.
- What they did: A retrospective cohort linked Medicare claims to SEER cancer registry data for SCLC diagnosed from 2015–2021 (follow-up through 2022), comparing 949 screened patients with 16,150 unscreened patients using propensity score-matched analyses.
- The result: Screened patients had significantly lower distant disease at diagnosis and significantly higher overall survival, with both results consistent after propensity score matching.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.